Stifel Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $30

Stifel analyst Stephen Willey maintains $Nurix Therapeutics(NRIX.US)$ with a buy rating, and adjusts the target price from $27 to $30.According to TipRanks data, the analyst has a success rate of 42.1

Moomoo NewsJul 16 22:32 ET · Ratings

Stifel Nicolaus Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

TipRanksJul 16 22:15 ET

JPMorgan Adjusts Price Target on Nurix Therapeutics to $34 From $31, Maintains Overweight Rating

Nurix Therapeutics (NRIX) has an average outperform rating and a price target range of $15 to $35, according to analysts polled by Capital IQ.Price: 23.45, Change: -0.37, Percent Change: -1.55

MT NewswiresJul 15 10:35 ET

Nurix Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 42.14% JP Morgan $31 → $34 Maintains Overweight 07/15/2024 29.6% Barclays $20 → $31 Maintains

BenzingaJul 15 09:55 ET

Nurix Therapeutics Is Maintained at Overweight by Barclays

Nurix Therapeutics Is Maintained at Overweight by

Dow JonesJul 15 09:14 ET

Express News | Nurix Therapeutics Inc. : Morgan Stanley Raises Target Price to $15.00 From $14.00

ReutersJul 15 09:07 ET